Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial
{{output}}
Background: Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS). ... ...
